APP and Alzheimer disease: The mechanisms by which OCYyoung-EVs improve AD pathology in APP/PS1 mice include the reduction in apoptosis in both the hippocampal neuron cell line HT22 and the human AD neuroblastoma cell line SH-SY5Y.